C5a receptor (CD88) blockade protects against MPO-ANCA GN

Journal of the American Society of Nephrology

Volumn 25, Issue 2, 2014, Pages 225-231

  Xiao, Hong ^a   Dairaghi, Daniel J ^b   Powers, Jay P ^b   Ertl, Linda S ^b   Baumgart, Trageen ^b   Wang, Yu ^b   Seitz, Lisa C ^b   Penfold, Mark E T ^b   Gan, Lin ^c   Hu, Peiqi ^a   Lu, Bao ^c   Gerard, Norma P ^d   Gerard, Craig ^d   Schall, Thomas J ^b   Jaen, Juan C ^b   Falk, Ronald J ^a   Jennette, J Charles ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ChemoCentryx Inc   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCX168; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5B; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; CROSS REACTION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; GENE SILENCING; HEMATURIA; IN VITRO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LEUKOCYTURIA; MOUSE; NECROTIZING AND CRESCENTIC GLOMERULONEPHRITIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECEPTOR BLOCKING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AUTOANTIGENS; COMPLEMENT C6; COMPLEMENT PATHWAY, ALTERNATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE KNOCK-IN TECHNIQUES; GLOMERULONEPHRITIS; HEMATURIA; HUMANS; IMMUNIZATION, PASSIVE; LEUKOCYTES; METABOLISM, INBORN ERRORS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXIDASE; PROTEINURIA; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, CHEMOKINE; RECOMBINANT FUSION PROTEINS; URINE;

EID: 84893502246     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013020143     Document Type: Article

References (24)

1. Jennette JC, Falk RJ, Hu P, Xiao H: Pathogenesis of anti-neutrophil cytoplasmic autoantibody associated small vessel vasculitis. Annu Rev Pathol 8:139-160, 2013
2. Jennette JC, Falk RJ, Gasim AH: Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 20:263-270, 2011
3. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955-963, 2002
4. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC: Alternative complement pathway in the pathogenesis of diseasemediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170:52-64, 2007
5. Huugen D, Van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P: Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 71:646-654, 2007
6. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20:289-298, 2009
7. Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, e J, Kallenberg CG, Zhao MH: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 29:282-291, 2009
8. Gigante A, Salviani C, Giannakakis K, Rosato E, Barbano B, Moroso A, Gasperini ML, Nofroni I, Salsano F, Cianci R, Pugliese F: Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: A single centre experience. Int J Immunopathol Pharmacol 25:287-292, 2012
9. Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 83:129-137, 2013
10. Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, Lim YS, Whitfeld PL, Craig S, Corsini E, Lu B, Gerard C, Gerard NP: The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 285:7633-7644, 2010
11. Chen M, Daha MR, Kallenberg CG: The complement system in systemic autoimmune disease. J Autoimmun 34:J276-J286, 2010
12. Hao J, Meng LQ, Xu PC, Chen M, Zhao MH: p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS ONE 7:e38317, 2012
13. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, Gerard C: An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 280:39677-39680, 2005
14. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN: The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol 46:1149-1162, 2009
15. Xiao H, Ciavatta D, Aylor DL, Hu P, De Villena FP, Falk RJ, Jennette JC: Genetically determined severity of anti-myeloperoxidase glomerulonephritis. Am J Pathol 182:1219-1226, 2013
16. Jennette JC: Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis). Clin Exp Immunol 164 [Suppl 1]: 7-10, 2011
17. Jennette JC, Falk RJ: The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 25 [Suppl 44]: S52-S56, 2007
18. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant roleforC5b-9inrenal ischemia/reperfusion injury. J Clin Invest 105:1363-1371, 2000
19. Carrera-Marín AL, Romay-Penabad Z, Papalardo E, Reyes-Maldonado E, García-Latorre E, Vargas G, Shilagard T, Pierangeli S: C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 21:1497-1505, 2012
20. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, Arend WP, Holers VM: Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 188:1469-1478, 2012
21. Fan P, Greenman KL, Leleti MR, Li Y, Powers J, Tanaka H, Yang J, Zeng Y: C5aR antagonists. US patent application WO2010075257. 2010
22. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ: Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 335:61-69, 2010
23. Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A, So T, Zwirner J, Koentgen F, Padkjaer SB, Mackay F, Whitfeld PL, Mackay CR: Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol 24:1279-1284, 2006
24. Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, Ertl LS, Zeng Y, Powers JP, Pennell AM, Bekker P, Schall TJ, Jaen JC: Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther 89:726-734, 2011